BIO TECHS?!?!Another classic set up that was been constantly rewarding investors long the risk reversal trade. Sector was been showing strength as you go down the cap scale.
high and tight holds probably
Next report date
Report period
Q1 2024
EPS estimate
−0.13CHF
Revenue estimate
32.31 MCHF
−0.255CHF
−55.62 MCHF
104.78 MCHF
223.70 M
About Ardelyx, Inc.
Sector
CEO
Michael G. Raab
Headquarters
Waltham
Website
Employees (FY)
267
Founded
2007
FIGI
BBG00LVD7Y62
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
ARDX Ardelyx Options Ahead of Earnings If you haven`t bought ARDS before it went up 6X:
Then analyzing the options chain and the chart patterns of ARDX Ardelyx prior to the earnings report this week,
I would consider purchasing the 4usd strike price Calls with
an expiration date of 2024-1-19,
for a premium of approximately $0.45.
If t
Focus on Biotechnology: Ardelyx Inc. Trading Idea for 19/10/2023Biotechnology company Ardelyx Inc. has received FDA approval for its drug Xphozah. This medication is intended for treating kidney diseases and is typically recommended for patients with elevated kidney phosphorus levels. Xphozah could be a valuable addition to hemodialysis therapy since it is compa
ARDX: Buy ideaBuy idea on ARDX as you see on the chart after the breakout with force the vwap indicator and the resistance line by a big green candle with a large green volume. In other hand, we will have a reversal trend if we have the breakout with force the support line by a big red candle with a large red vol
ARDX Strong upgrade from a top financial firmARDX Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the US and internationally.
On 3/2/2022 Jefferies Financial Group Upgraded ARDX from Hold to Buy raising the price target from $1.00 to $
ARDXLooking at 1-hour chart
hit resistant of 2.80
Pulling back
Looking for an entry around 2.63
Potential Gap UP
Cup and handle formation?Breakout above 2.2? and possible gap fill toward upside.
The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9:4, with the majority favoring treatment with the drug as monotherapy.
FDA decision soon. Risk is traditional sell the news event.
ARDX | InformativeNASDAQ:ARDX
If it passes the bearish line it's time for a short position, and if it passes the bullish line it's time for the Long position, the price targets are on the chart.
$ARDX textbook wedge This trade is not actionable without volume confirmation, wedge breakout, and ofc a SET SL AND TP
ALSO looking at GAP fill over $2.00+
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 41X is 6.755 CHF — it has decreased by 9.62% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange ARDELYX INC stocks are traded under the ticker 41X.
ARDELYX INC is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
41X stock is 10.64% volatile and has beta coefficient of 2.22. Check out the list of the most volatile stocks — is ARDELYX INC there?
41X earnings for the last quarter are 0.03 CHF per share, whereas the estimation was −0.10 CHF resulting in a 127.89% surprise. The estimated earnings for the next quarter are −0.08 CHF per share. See more details about ARDELYX INC earnings.
ARDELYX INC revenue for the last quarter amounts to 51.63 M CHF despite the estimated figure of 20.66 M CHF. In the next quarter revenue is expected to reach 28.68 M CHF.
Yes, you can track ARDELYX INC financials in yearly and quarterly reports right on TradingView.
41X net income for the last quarter is −24.25 M CHF, while the quarter before that showed 6.07 M CHF of net income which accounts for −499.57% change. Track more ARDELYX INC financial stats to get the full picture.
Today ARDELYX INC has the market capitalization of 1.36 B, it has decreased by 6.20% over the last week.
No, 41X doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 41X shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ARDELYX INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 267.00 employees. See our rating of the largest employees — is ARDELYX INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ARDELYX INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ARDELYX INC stock shows the sell signal. See more of ARDELYX INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ARDELYX INC future price: according to them, 41X price has a max estimate of 14.59 CHF and a min estimate of 10.03 CHF. Read a more detailed ARDELYX INC forecast: see what analysts think of ARDELYX INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ARDELYX INC EBITDA is −49.92 M CHF, and current EBITDA margin is −49.80%. See more stats in ARDELYX INC financial statements.